←
Sara Coca Membribes1,262 posts
Sara Coca Membribes avatar

Sara Coca Membribes

@scocmem

🧩 Medical Oncologist | #GUOncology Clinical Research Fellow |📍Barts Cancer Institute @BartsECMC @QMBCI

◷ Joined August 2025▧ 112 Photos and videos
Brian Rini, MD avatar
⟳ Sara Coca Membribes retweeted
Brian Rini, MD@brian_rini·Nov 17

All #UromigosLIVE sessions are also podcasts. Available in English on our Uromigos channel and in Spanish on the separate Los Uromigos channel.

That’s a wrap on Uromigos Live in Nashville! The weekend was packed with lively debates, insightful conversations, and a little friendly competition at The Uromigos Live World Cup. Looking for Spanish-language coverage of the weekend? You’ll find it all on @LosUromigos 🎙️

Post attachment
Uromigos avatar
⟳ Sara Coca Membribes retweeted
Uromigos@Uromigos·19h

Can patients with muscle-invasive bladder cancer avoid radical cystectomy? From radical cystectomy to bladder-sparing approaches, the debate took center stage at #UromigosLive in Nashville 🎸 Listen to the full discussion ⬇️ 🎧 Apple: apple.co/4t9r8Ps 🎧 Spotify: bit.ly/4iPpf6Q

Post attachment
Paolo Tarantino avatar
⟳ Sara Coca Membribes retweeted
Paolo Tarantino@PTarantinoMD·Nov 16

Impressive continuity (500+!) and outstanding quality for this podcast — which is supposed to be Uro-focused, but from which there’s actually a lot to learn across disease areas. Congrats!! @tompowles1 @brian_rini

🎉🎙️ 500+ EPISODES AND COUNTING! 🏆 Huge congratulations to @brian_rini & @tompowles1 on this incredible milestone with @Uromigos! 👏👏 🌎 500+ episodes connecting the global #GUOncology community through outstanding science, insightful debates, sharp questions, and genuine friendship. ❤️ What an extraordinary contribution to education, collaboration, and better cancer care! 🎸 Celebrating together at #UromigosLive Nashville 2026! @OncoAlert @LosUromigos @brian_rini @tompowles1 @Uromigos @LosUromigos @ASCO @UrologyTimes @urotoday @ecancer @IUCS @MattGalsky @MichvdHeijden @shilpaonc @DrRosenbergMSK @JoshMeeks @kalasri3 @PGrivasMDPhD @NehaVapiwala @TDorffOnc @AttardLab @neerajaiims @lalaniMD @DrKarieRuncie @TiansterZhang @MVossMD @montypal @HHammersMD @AlbigesL @ViktorGruenwald @dr_coops @yao_zhu_sh @AmandaNizamMD @Dr_Aggen @NazliDizman @katy_beckermann @TwoOncDocs @DrKarineTawagi @weoncologists @gbanna74 @ravikanesvaran #GUcancer #Oncology #MedTwitter

Post attachment
Anirban Maitra avatar
⟳ Sara Coca Membribes retweeted
Anirban Maitra@Aiims1742·Nov 16

Daraxonrasib is now approved in the second line and beyond in metastatic #PancreaticCancer in the European Union. Good news for patients across the pond! @RevMedicines @KRASKickers revmed.com/media/news/13736/…

Uromigos avatar
⟳ Sara Coca Membribes retweeted
Uromigos@Uromigos·Nov 16

That’s a wrap on Uromigos Live in Nashville! The weekend was packed with lively debates, insightful conversations, and a little friendly competition at The Uromigos Live World Cup. Looking for Spanish-language coverage of the weekend? You’ll find it all on @LosUromigos 🎙️

Post attachment
Shilpa Gupta, MD, FASCO avatar
⟳ Sara Coca Membribes retweeted
Shilpa Gupta, MD, FASCO@shilpaonc·Nov 14

Brings attention to the huge unmet need in UTUC! We need a dedicated adjuvant trial with an ADC-IO! We had a great @Uromigos podcast with @tompowles1 & @brian_rini to discuss Tom's famous tweet on adjuavnt UTUC preferred tx option with 4 equally split votes! open.spotify.com/episode/29G… Time for coop group to take this on! @eaonc @PGrivasMDPhD @MonikaJoshimd Stay tuned 😊 @YigeBao @niklas_kluemper @AlisonBirtle

Post attachment

Spirited debate between @LAUrology_NL & @YigeBao re: IO v chemo for UTUC. Love the @Uromigos format for the #UromigosCup this year! Glad I am not competing again - this competition much tougher … @tompowles1 @brian_rini @OncoAlert

Post attachmentPost attachmentPost attachment
Niklas Klümper avatar
⟳ Sara Coca Membribes retweeted
Niklas Klümper@niklas_kluemper·Nov 16

Exciting new directions in 1L mRCC! 🧬 Particularly interesting to see PD-1×VEGF bispecifics entering the RCC landscape. However, following the recent FDA setback for ivonescimab in NSCLC, an important reminder: promising early activity and PFS signals are not enough—we need durable survival benefit and favorable tolerability. After several disappointing triplet trials, perhaps the future is not simply adding more drugs, but better patient selection and smarter combinations. And most importantly: how can we identify patients who achieve durable IO-driven remission and potentially avoid chronic TKI toxicity? Great discussion at #UromigosLive! 👏 @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

Beyond the usual triplets, 3 new ideas in 1L mRCC #kidneycancer to watch #UromigosLive:🔹Ivonescimab (PD-1/VEGF bispecific) ph1🔹PEAK-20 ph3:casdatifan added to ipi/nivo🔹PDIGREE Ph3: ORR-adapted ipi/nivo, then nivo ± cabo👉@Uromigos @OncoAlert @brian_rini @tompowles1 @montypal

Post attachmentPost attachmentPost attachmentPost attachment
OncoAlert avatar
⟳ Sara Coca Membribes retweeted
OncoAlert@OncoAlert·Nov 16

The OncoAlert 🚨 Coverage of #UromigosLIVE 🎸 2026 ctDNA: can we spare adjuvant EV? Dr. Jonathan Rosenberg 🇺🇸 @DrRosenbergMSK of @MSKCancerCenter discusses with Dr. Michiel van der Heijden🇳🇱 @MichvdHeijden of @NKI_nl on how he uses ctDNA in MIBC today: 🔹 Mostly post-op, based on IMvigor011: it helps risk-stratify patients, especially after an excellent pathologic response to neoadjuvant therapy 🔹 Rising ctDNA before surgery is a very bad sign. Consider other approaches before cystectomy 🔹 Clear before surgery, negative after and staying negative: these patients do really, really well 🔹 Bladder preservation cuts both ways. Persistently positive patients likely fail distantly, but some clear their ctDNA with surgery. Would they also clear with chemoradiation or more EV-P? EV-209, EV-309 and sac-TMT + pembro trials should help answer this 🔹 ctDNA down but not cleared → go to surgery, then continue adjuvant therapy 💬 "Surgery is curing patients. It's just not curing all patients." 💡 After VOLGA, he's more likely to drop adjuvant EV: great neoadjuvant response + ctDNA-negative after surgery → most are probably cured. Less EV means less toxicity, and some of it is long-term. Would you de-escalate adjuvant EV based on ctDNA? 👇 #BladderCancer #MIBC #ctDNA #GUOnc @Uromigos, @tompowles1, @brian_rini, @shilpaonc, @montypal, @TiansterZhang, @neerajaiims, @katy_beckermann, @PGrivasMDPhD, @TwoOncDocs, @DrKarineTawagi, @nataliagandur, @Dr_Aggen, @AmandaNizamMD, @scocmem, @lalaniMD, @NazliDizman, @weoncologists, @LosUromigos, @uromigosjapan

5:17
Adam Feuerstein ✡️ avatar
⟳ Sara Coca Membribes retweeted
Adam Feuerstein ✡️@adamfeuerstein·Nov 15

FDA rejected $SMMT ivonescimab. No survival benefit in mEGFR lung cancer, no approval. smmttx.com/news/press-releas…

Los Uromigos avatar
⟳ Sara Coca Membribes retweeted
Los Uromigos@LosUromigos·Nov 14

⭐🟢 #UromigosLive 2026 | Nashville 🎸 🚨 ENGANCHADORES DE CÉLULAS T EN CÁNCER RENAL: ¿Estamos ante un nuevo paradigma? 🔬 XmAb819, anticuerpo biespecífico ENPP3 × CD3, busca redirigir los linfocitos T contra las células tumorales. 📊 Resultados preliminares fase I: ✅ Respuesta objetiva confirmada: 45,5% con 400 μg/kg (n=11). ✅ SLP estimada a 6 meses: 82%. ✅ Actividad prometedora en pacientes previamente tratados. ⚠️ La toxicidad sigue siendo un desafío: síndrome de liberación de citocinas, especialmente durante la fase inicial del tratamiento. 💡 Mensaje clínico: La redirección de células T podría ampliar las opciones terapéuticas en cáncer renal refractario. Todavía necesitamos confirmar eficacia, duración de respuesta y seguridad en estudios de mayor tamaño. 🎙️ Excelente debate con Brian Rini, Monty Pal, Hans Hammers, David McDermott y James Larkin. @Uromigos @OncoAlert @tompowles1 @brian_rini @montypal @HHammersMD @MVossMD @TiansterZhang @AlbigesL #CancerRenal #OncologiaGU #GUOncology #Inmunoterapia

Post attachment
Los Uromigos avatar
⟳ Sara Coca Membribes retweeted
Los Uromigos@LosUromigos·Nov 14

⭐🟢 #UromigosLive 2026 🎸 | Nashville 🔬 PEAK-20: ¿UNA NUEVA GENERACIÓN DE TRIPLETES EN CÁNCER RENAL METASTÁSICO? 🔥 ¡Continúa el debate sobre el futuro del tratamiento de primera línea! Tras los resultados decepcionantes de diferentes estrategias triples, PEAK-20 propone una nueva combinación basada en la inhibición de HIF-2α. 📊 PEAK-20 | Fase III | N previsto=660 ✅ Casdatifan + nivolumab + ipilimumab frente a nivolumab + ipilimumab. ✅ Pacientes con carcinoma renal de células claras avanzado o metastásico, sin tratamiento sistémico previo para enfermedad metastásica. ✅ Incluye todos los grupos de riesgo IMDC. 🎯 Objetivo primario: supervivencia libre de progresión. 🔬 Objetivos secundarios: supervivencia global, respuesta objetiva, duración de respuesta, control de enfermedad y seguridad. 💡 Reflexión clínica: No se trata simplemente de sumar un tercer fármaco, sino de incorporar un mecanismo de acción diferente que pueda mejorar los resultados manteniendo una toxicidad aceptable. ⚠️ El estudio está planificado y todavía debe demostrar su beneficio clínico. 🎸 ¡Excelente intercambio científico y nuevas preguntas para la investigación en cáncer renal! @LosUromigos @Uromigos @tompowles1 @brian_rini @OncoAlert @montypal @HHammersMD @AlbigesL @MVossMD @TiansterZhang @ViktorGruenwald @nataliagandur @weoncologists #UromigosLive #CancerRenal #KidneyCancer #RCC #OncologiaGU #InvestigacionClinica

Post attachmentPost attachment
Uromigos avatar
⟳ Sara Coca Membribes retweeted
Uromigos@Uromigos·Nov 14

There are now 2 (EVP and EVD) FDA approved regimens available in MIBC . The panel @tompowles1 @shilpaonc @MichvdHeijden @kalasri3 @DrRosenbergMSK @MattGalsky @PGrivasMDPhD @JoshMeeks Anna Wilkins Rough conclusion from #UromigosLive : 👉Both these regimens are better than any other option. Both trials are robust and very positive. Both are a reasonable approach. EV/D 1st ask questions later @MichvdHeijden 👉EVP gives you the flexibility to give the adjuvant period if you want, and some may need it, especially the higher TNM stage. Biomarkers don’t help @DrRosenbergMSK 👉It’s not clear who needs the adjuvant period, but 9 cycles is not for everyone. Most in the trials didn’t get to 9 cycles @shilpaonc 👉EVD does not have the adjuvant ADC period and will be attractive for some patients and doctors. 👉Stick to the protocol and don’t let ctDNA or pCR or TMT take you off course too much @MosheOrnsteinMD 👉Bladder sparing are already attractive @kalasri3 but let’s wait for the trial results @MattGalsky 👉’Pick one and use it well’ maybe more imporant than the deliberation over the optimal regimen as it’s true that only half the pateint finish the IO therapy. @tompowles1

Post attachment